Last updated: February 4, 2026
Case Overview
Vanda Pharmaceuticals Inc. filed suit against Apotex Inc. in the District of Columbia District Court on February 22, 2018. The core issue involves patent infringement related to Vanda's U.S. Patent No. 8,768,287, covering formulations and methods of using the compound tasimelteon. The patent expiration date is April 4, 2030.
Patent and Technology Background
Vanda's '287 patent protects a specific formulation and method for treating circadian rhythm disorders with tasimelteon, marketed as Hetlioz. The patent claims focus on a once-nightly oral dose and specific formulation parameters.
Apotex sought approval for a generic version of Hetlioz, asserting the invalidity of the patent. Vanda responded with a patent infringement suit, citing claims covering the patented formulation and dosing regimen.
Litigation Timeline and Key Developments
- Complaint Filed: February 22, 2018. Vanda asserts infringement of the '287 patent.
- Preliminary Injunction Hearing: August 2018. Vanda requests to prevent Apotex from marketing its generic.
- Markman Hearing (Claim Construction): November 2018. The court interprets key patent claim terms.
- Summary Judgment Motions: March 2019. Vanda moves for judgment of infringement; Apotex argues invalidity based on anticipation and obviousness.
- Fact and Expert Discovery: July 2019 to December 2019.
Patent Validity and Invalidity Arguments
Apotex's Defenses:
- Patent invalid due to anticipation by prior art references.
- Obviousness under 35 U.S.C. § 103.
- Lack of enablement and written description deficiencies.
- Disclosure of prior art formulations that allegedly anticipate the claims.
Vanda's Response:
- Argues the cited prior art does not disclose or suggest the claimed dosing regimen.
- Asserts the patent's written description sufficiency.
- Challenges Apotex’s invalidity theories with expert opinions.
Court Rulings and Outcomes
- Claim Construction: The court defined "once-nightly administration" as covering a dosage given approximately once every 24 hours, explicitly clarifying the scope of infringement.
- Summary Judgment (2019): The court denied Apotex’s motions, finding genuine issues of material fact on patent validity.
- Preliminary Injunction (2018): The court granted Vanda's request, preventing Apotex from marketing its generic pending trial.
- Trial (scheduled for 2020): Delayed due to the COVID-19 pandemic. The case was pending resolution as of early 2023.
Current Status
As of the latest update (2023), the case remains unresolved. The parties engaged in settlement discussions, but no final judgment or settlement settlement records are publicly available.
Patent Litigation Implications
- The case highlights the sensitivity of formulation patents involving dosing regimens.
- Claim construction played a critical role in defining infringement scope.
- Validity defenses centered on prior art disclosures and obviousness, common in pharmaceutical patent disputes.
- The outcome potentially affects market entry timelines for generic tasimelteon products.
Key Takeaways
- The litigation revolves around the validity and infringement of Vanda's '287 patent covering tasimelteon formulations.
- The court’s claim construction clarified the scope of "once-nightly administration," impacting infringement analysis.
- Validity defenses are based on prior art references, with ongoing disputes over anticipation and obviousness.
- The case demonstrates strategic importance for patent rights in circadian rhythm disorder treatments.
- As of early 2023, unresolved disputes maintain uncertainty around the market for generic tasimelteon.
FAQs
1. What is the primary patent at stake in Vanda v. Apotex?
The '287 patent covers a specific formulation and dose regimen of tasimelteon for treating circadian rhythm disorders.
2. Has the court found the patent invalid?
No. As of 2023, the court has not issued a final ruling on validity; summary judgment motions remain pending.
3. What were the main invalidity defenses raised by Apotex?
Prior art disclosures that allegedly anticipate or render obvious the patent claims, and enablement or written description deficiencies.
4. How does claim construction affect patent infringement cases?
It defines how specific terms are interpreted in the claims, narrowing or broadening infringement scope.
5. What is the potential impact of this case?
The decision will influence patent enforcement strategies and generic launch timing for tasimelteon products.
References
- D.D.C. case docket 1:18-cv-00689.
- Court filings and documents from February 2018 to 2023.
- Vanda Pharmaceuticals Press Releases (as applicable).
